The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1728
May 12, 2025
View Complete Issue         Table of Contents 2019 
Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening
May 12, 2025 (Issue: 1728)
The FDA has approved Cologuard Plus (Exact Sciences), a new at-home multitarget stool DNA test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Cologuard, the first FDA-approved multitarget stool DNA test, has been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening
Article code: 1728a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.